News
About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...
More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.
A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...
5d
MedPage Today on MSNGLP-1 Drugs May Help in Fibromyalgia, Large Records Study SuggestsBARCELONA -- A rheumatology trainee who went on TikTok to find information on her own condition may have uncovered a novel ...
A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic ...
New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...
Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists across multiple studies.
Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP ...
18h
News-Medical.Net on MSNDiabetes medication shows promise in cutting migraine days by more than halfA diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...
10d
Medindia on MSNDiabetes Drug Semaglutide Linked to Vision Loss RiskNew research shows GLP-1 drugs may be linked to a twofold increase in the risk of wet AMD among people with diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results